Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$191 Mln
P/E Ratio
--
P/B Ratio
2.8
Industry P/E
--
Debt to Equity
0.89
ROE
-0.85 %
ROCE
-56.9 %
Div. Yield
0 %
Book Value
0.82
EPS
-0.8
CFO
$-110.32 Mln
EBITDA
$-168.41 Mln
Net Profit
$-236.14 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Codexis (CDXS)
| -51.15 | -20.21 | -50.64 | -12.41 | -42.63 | -27.33 | -6.39 |
|
BSE Sensex*
| 2.76 | 3.87 | 5.94 | 9.06 | 11.81 | 20.15 | 11.37 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Codexis (CDXS)
| 55.82 | -34.55 | -85.10 | 43.24 | 36.52 | -4.25 | 99.25 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.44 | 10,315.11 | 21.27 | 23.13 | |
| 298.18 | 8,705.27 | 22.77 | 66.44 | |
| 27.46 | 10,589.59 | -- | -28.77 | |
| 106.46 | 10,559.67 | 32.44 | 14.16 |
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle... East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California. Address: 200 Penobscot Drive, Redwood City, CA, United States, 94063 Read more
President, CEO & Director
Dr. Stephen George Dilly MBBS, Ph.D.
President, CEO & Director
Dr. Stephen George Dilly MBBS, Ph.D.
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Codexis Inc (CDXS) stood at $ 149 Mln as on 31-Dec-24
The share price of Codexis Inc (CDXS) is $2.33 (NASDAQ) as of 28-Apr-2025 16:00 EDT. Codexis Inc (CDXS) has given a return of -42.63% in the last 3 years.
Codexis Inc (CDXS) has a market capitalisation of $ 191 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Codexis Inc (CDXS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Codexis Inc (CDXS) and enter the required number of quantities and click on buy to purchase the shares of Codexis Inc (CDXS).
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California. Address: 200 Penobscot Drive, Redwood City, CA, United States, 94063
The CEO & director of Dr. Stephen George Dilly MBBS, Ph.D.. is Codexis Inc (CDXS), and CFO & Sr. VP is Dr. Stephen George Dilly MBBS, Ph.D..
There is no promoter pledging in Codexis Inc (CDXS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Codexis Inc. (CDXS) | Ratios |
|---|---|
|
Return on equity(%)
|
-85.03
|
|
Operating margin(%)
|
-98.33
|
|
Net Margin(%)
|
-109.99
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Codexis Inc (CDXS) was $0 Mln.
$0.07
(
